Expression of the serine protease inhibitor serpinA3 in human colorectal adenocarcinomas

Dimberg,Jan; Ström,Karin; Löfgren,Sture; Zar,Niklas; Hugander,Anders; Matussek,Andreas

doi:10.3892/ol.2011.280

Expression of the serine protease inhibitor serpinA3 in human colorectal adenocarcinomas

Authors:
- Jan Dimberg
- Karin Ström
- Sture Löfgren
- Niklas Zar
- Anders Hugander
- Andreas Matussek
View Affiliations

Affiliations: Department of Natural Science and Biomedicine, University College of Health Sciences, Box 1026, SE-551 11 Jönköping, Sweden, Department of Clinical Microbiology, Ryhov County Hospital, SE-551 11 Jönköping, Sweden, Department of Surgery, Ryhov County Hospital, SE-551 11 Jönköping, Sweden, Department of Laboratory Medicine, Ryhov County Hospital, SE-551 11 Jönköping, Sweden
Published online on: March 21, 2011 https://doi.org/10.3892/ol.2011.280
Pages: 413-418

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Proteases facilitate a number of steps in cancer progression. The serine protease inhibitors (serpins) are a protein superfamily with inhibitory activity against proteases. One of these proteases, serpinA3, appears to have a multifaceted role and is associated with inflammatory reactions, Alzheimer's disease, malignant melanoma and gastric cancer. To gain insight into the potential effect of serpinA3 on colorectal cancer (CRC) we determined whether serpinA3 is altered in colorectal tissue or plasma in CRC patients. Collectively, by using ELISA we noted a significantly lower serpinA3 level in cancer tissue compared to paired normal tissue. Moreover, the tumour serpinA3 level tended to be higher in disseminated disease as compared to localised disease. No significant difference in the plasma levels of serpinA3 was noted in the patients when compared to the controls. However, plasma serpinA3 and C-reactive protein (marker of inflammation) in the CRC patients and controls were significantly positively correlated. To confirm and detect localization of serpinA3 expression, immunohistochemistry was performed. Immunohistochemistry showed heterogeneous immunoreactivity in epithelial cells in the cancer and normal tissue and extracellular staining within bands of stroma as well as in some stromal cells. A Taq Man system was used to investigate a single nucleotide polymorphism (rs4934) in the serpinA3 signal sequence gene with supposed effect on serpinA3 secretion and expression. No significant difference was observed between CRC and control subjects regarding genotype and allelic distributions, nor were associations noted between clinical characteristics and serpinA3 levels. In conclusion, an altered serpinA3 concentration in CRC tissue may be a potential biomarker in CRC progression. SerpinA3 concentrations in plasma appear to be correlated with systemic inflammation, but do not appear to be specific to CRC patients. Further studies are warranted to improve our understanding of the role of serpinA3 in CRC.

View Figures

View References

1	Lopez-Otin C and Matrisian LM: Emerging roles of proteases in tumour suppression. Nat Rev Cancer. 7:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
2	Stetler-Stevenson WG: The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin N Am. 10:383–392. 2001.PubMed/NCBI
3	Murray GI, Duncan ME, O’Neil P, Melvin WT and Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med. 2:461–462. 1996. View Article : Google Scholar : PubMed/NCBI
4	Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM and Pyrhonen S: High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer. 97:432–438. 2002. View Article : Google Scholar : PubMed/NCBI
5	Kuester D, Lippert H, Roessner A and Krueger S: The cathepsin family and their role in colorectal cancer. Pathol Res Pract. 204:491–500. 2008. View Article : Google Scholar : PubMed/NCBI
6	Law RHP, Zhang Q, McGowan S, Buckle AM, Silverman GA, Wong W, Rosado CJ, Langendorf CG, Pike RN, Bird PI and Whisstock JC: An overview of the serpin superfamily. Genome Biol. 7:2162006. View Article : Google Scholar : PubMed/NCBI
7	Gettins PG: Keeping the serpin machine running smoothly. Genome Res. 10:1833–1835. 2000. View Article : Google Scholar : PubMed/NCBI
8	Kalsheker NA: Alpha-1-antichymotrypsin. Int J Biochem Cell Biol. 28:961–964. 1996. View Article : Google Scholar
9	Janciauskiene S: Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. Biochim Biophys Acta. 1535:221–235. 2001. View Article : Google Scholar
10	Allgayer H, Babic R, Grutzner KU, Beyer BCM, Tarabichi A, Schildberg FW and Heiss MM: Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis. 16:62–73. 1998. View Article : Google Scholar : PubMed/NCBI
11	Kamboh ML, Minster RL, Kenney M, Ozturk A, Desai PP, Kammerer CM and DeKosky ST: Alpha-1-antichymotrypsin (ACT or SERPINA3) polymorphism may affect age-at-onset and disease duration of Alzheimer’s disease. Neurobiol Aging. 27:1435–1439. 2006.
12	Slowik A, Borratynska A, Turaj W, Pera JP, Dziedzic T, Figlewicz DA, Betlej M, Krzyszkowski T, Czepko R and Szczudlik A: Alpha-1-antichymotrypsin gene (SERPINA3) A/T polymorphism as a risk factor for aneurysmal subarachnoid hemorrhage. Stroke. 36:737–740. 2005. View Article : Google Scholar : PubMed/NCBI
13	Liu W, Zhu Y, Ge M, Pang Q and Yu Y: Polymorphism rs4934 of SERPINA3 and sporadic intracranial aneurysms in the Chinese population. Cerebrovasc Dis. 29:68–72. 2010. View Article : Google Scholar : PubMed/NCBI
14	Krischek B, Akagawa H, Tajima A, Narita A, Kasuya H, Hori T and Inoue I: The alanine/threonine polymorphism of the alpha-1-antichymotrypsin (SERPINA3) gene and ruptured intracranial aneurysms in the Japanese population. Cerebrovasc Dis. 23:46–49. 2007. View Article : Google Scholar : PubMed/NCBI
15	Erlinger TP, Platz EA, Rifai N and Helzlsouer KJ: C-reactive protein and the risk of incident colorectal cancer. JAMA. 291:585–590. 2004. View Article : Google Scholar : PubMed/NCBI
16	Wilson TJ, Nannuru KC and Singh RK: Cathepsin G-mediated activation of pro-matrix metalloproteinase 9 at the tumor-bone interface promotes transforming growth factor-β signaling and bone destruction. Mol Cancer Res. 7:1224–1233. 2009.PubMed/NCBI
17	Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, Syrjänen K, Collan Y and Pyrhönen S: MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest. 28:38–43. 2010. View Article : Google Scholar : PubMed/NCBI
18	Wang Y, Jiang H, Dai D, Su M, Martinka M, Brasher P, Zhang Y, McLean D, Zhang J, Ip W, Li G, Zhang X and Zhou Y: Alpha 1 antichymotrypsin is aberrantly expressed during melanoma progression and predicts poor survival for patients with metastatic melanoma. Pigment Cell Melanoma Res. 23:575–578. 2010. View Article : Google Scholar : PubMed/NCBI
19	Castell JV, Gomez-Lechon MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R and Heinrich PC: Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 242:237–239. 1989. View Article : Google Scholar : PubMed/NCBI
20	Chung YC and Chang YF: Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 83:222–226. 2003. View Article : Google Scholar : PubMed/NCBI
21	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
22	Balkwill F: Chemokine biology in cancer. Semin Immunol. 15:49–55. 2003. View Article : Google Scholar : PubMed/NCBI
23	Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A and Boffetta P: Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 15:381–384. 2006. View Article : Google Scholar : PubMed/NCBI